Elevance Health, Inc. (ELV) is positioned for growth with premium rate adjustments in the Health Benefits business, an expanding external pharmacy membership base and overall strength in the Carelon business. The BioPlus acquisition is expected to continue supporting the Carelon unit’s performance.Elevance — with a market cap of $111.6 billion — is one of the largest publicly traded health benefits companies in the United States. Courtesy of solid prospects, this currently Zacks Rank #3 (Hold) stock is wort ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?T ...

The most recent trading session ended with Elevance Health (ELV) standing at $475.12, reflecting a -1.49% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.02%.The the stock of health insurer has risen by 0.51% in the past month, lagging the Medical sector's gain of 6.57% and the S&P 500's gain of 3.52%.Analysts and investors alike will be keeping a close eye on the per ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Elevance Health, Inc. (ELV) recently announced that it will launch a program in which high-quality smartphones will be provided to qualifying individuals enrolled in its Medicaid health plan. Elevance Health disclosed, in the Consumer Electronics Show 2024, that eligible individuals will get unlimited texting, talking and data service for free, enhancing ELV’s offerings.This move bodes well for Elevance Health as it will be able to bridge the gap between people who have access to smartphones and those who d ...

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced that it has entered into an agreement to acquire Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. For more than 20 years, Paragon Healthcare has provided infusion services to patients through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The company, headquartered in Plano, Texas, provides hig ...

Financial Data and Key Metrics Changes - The company reported third quarter GAAP earnings per share of $5.45, reflecting a strong performance despite a charge taken during the quarter [64] - Adjusted earnings per share was $8.99, showing growth of approximately 20% over the third quarter of 2022 [107] - Operating revenue in the third quarter was $42.5 billion, an increase of 7.2% over the prior year quarter, driven by rate increases and double-digit growth in CarelonRx [123] Business Line Data and Key Metrics Changes - The Health Benefits division delivered robust results, with operating margin improvement of 30 basis points year-over-year [126] - CarelonRx achieved 17.5% revenue growth, propelled by growth in pharmacy customers and the acquisition of BioPlus [126] - The individual membership grew by 27% year-to-date, with ACA membership growth rate more than tripling that of competitors in the 14 Blue states [110] Market Data and Key Metrics Changes - Nearly three-quarters of Medicaid beneficiaries terminated in the company's markets have lost coverage for administrative reasons, with 37% of attrition driven by individuals under 18 [68] - The company expects re-enrollment to accelerate in the coming quarters, anticipating a slowdown in membership attrition associated with redeterminations [69] - The company is seeing encouraging signs in some Blue states, with over 30% of Medicaid members who were terminated returning or retaining coverage [79] Company Strategy and Development Direction - The company is focused on enhancing operating efficiency and optimizing its physical footprint, resulting in a business optimization charge of approximately $700 million [52] - The strategy includes investments in technology and automation to improve service delivery and member experience [85] - The company is committed to delivering whole health solutions that are affordable, personalized, and simple, with a long-term target compound annual growth rate in adjusted earnings per share of 12% to 15% [65] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with recent Star quality ratings but remains committed to improving this line of business for the long term [96] - The company anticipates continued momentum in Carelon, driven by new product launches and the ramp-up of BioPlus [97] - Management is confident in the ability to deliver strong growth in adjusted earnings per share in 2024, despite headwinds related to Medicaid membership attrition [119] Other Important Information - The company is on track to launch its advanced home delivery capability in the fourth quarter, enhancing consumer experiences and affordability [115] - The integration of BioPlus is ahead of schedule, with plans to migrate specialty scripts from the legacy pharmacy platform early next year [82] - The company has repurchased approximately 1.1 million shares of common stock for $480 million during the quarter [127] Q&A Session Summary Question: Can you discuss the commercial margin improvement story and underlying cost trends? - Management noted that the team has balanced membership retention and margin improvements, indicating a multiyear journey in the commercial business [4] Question: How is Medicaid disenrollment trending compared to expectations? - Management indicated that Medicaid disenrollment has been front-loaded, with many members returning after temporary disenrollment [8][10] Question: What are the expectations for Medicare Advantage membership growth? - Management stated that it is too early to provide specific guidance but is optimistic about growth based on early responses from brokers [31][162] Question: How is the company addressing the recent decline in Star ratings? - Management acknowledged disappointment in Star ratings and is committed to improving quality measures through value-based care initiatives [102][112] Question: What actions are being taken to mitigate financial impacts for 2025? - Management is exploring contract diversification, operating efficiencies, and capital deployment alternatives to address potential financial impacts [81][137]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Elevance Health, Inc. (NYSE:ELV) Q2 2023 Earnings Conference Call July 19, 2023 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO John Gallina - CFO Peter Haytaian - President of Carelon Morgan Kendrick - President of Commercial and Specialty Health Benefits Division Felicia Norwood - President of Government Health Benefits Division Conference Call Participants A.J. Rice - Credit Suisse Lance Wilkes - Bernstein Justin Lake - Wolfe Research Michael Ha - Morgan Stanley ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 ELEVANCE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...